Results 261 to 270 of about 209,459 (341)

Observable score for bleeding after colorectal endoscopic mucosal resection. [PDF]

open access: yesTherap Adv Gastroenterol
Nakazawa H   +14 more
europepmc   +1 more source

Hemostasis in Cardiac Surgery.

open access: bronze, 2000
Linda Shore‐Lesserson
openalex   +1 more source

Intravascular Lithotripsy for Coral Reef Aorta and Chronic Mesenteric Ischemia: Case Report and Comprehensive Literature Review

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Chronic mesenteric ischemia (CMI) secondary to extensive paravisceral atherosclerosis is a rare but challenging vascular condition, often presenting with postprandial abdominal pain, weight loss, and claudication due to impaired blood flow. While surgical bypass is a standard treatment, it carries significant risks, particularly in patients ...
Dipankar Mukherjee   +2 more
wiley   +1 more source

Blood hemostasis in exercise and training

open access: bronze, 2000
MAHMOUD S. EL-SAYED   +3 more
openalex   +1 more source

Is Aortic Balloon Occlusion Effective to Reduce Blood Loss During Lower Lumbar Tumor Resection?

open access: yesCancer Nexus, EarlyView.
ABSTRACT Purpose In this study, we evaluated the efficacy and safety of using an aortic balloon to control blood loss during lower lumbar tumor resection. Methods We retrospectively reviewed 82 patients with tumors involving the lower lumbar spine (L4, L5, or Both), who were treated at our center from July 2015 to September 2023.
Jiacheng Chen   +7 more
wiley   +1 more source

First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Endogenous oxytocin plays an important role in lactation, but its effectiveness as an exogenous galactagogue has been modest due to dose‐limiting side effects related to off‐target effects at the vasopressin V2 receptor. Merotocin (FE 202767) is a short‐acting peptidic oxytocin receptor agonist with the potential to aid mothers experiencing ...
Yu Bagger   +4 more
wiley   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy